Cargando…

The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice

Obesity and diabetes are major causes of morbidity and mortality globally. The current study builds upon our previous association studies highlighting that A Disintegrin And Metalloproteinase 28 (ADAM28) appears to be implicated in the pathogenesis of obesity and type 2 diabetes in humans. Our novel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herat, Lakshini, Rudnicka, Caroline, Okada, Yasunori, Mochizuki, Satsuki, Schlaich, Markus, Matthews, Vance
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412464/ https://www.ncbi.nlm.nih.gov/pubmed/28430139 http://dx.doi.org/10.3390/ijms18040884

Ejemplares similares

Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes
por: Matthews, Jennifer, et al.
Publicado: (2021)

Overexpression and knock-down studies highlight that a disintegrin and metalloproteinase 28 controls proliferation and migration in human prostate cancer
por: Rudnicka, Caroline, et al.
Publicado: (2016)

ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice
por: Weerasekera, Lakshini, et al.
Publicado: (2017)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
por: Matthews, Jennifer, et al.
Publicado: (2023)

Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition
por: Herat, Lakshini Y., et al.
Publicado: (2022)

Sympathetic stimulation with norepinephrine may come at a cost
por: Herat, Lakshini Y., et al.
Publicado: (2019)

The Sympathetic Nervous System Regulates Sodium Glucose Co-Transporter 1 Expression in the Kidney
por: Matthews, Jennifer, et al.
Publicado: (2023)

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy
por: Herat, Lakshini Y., et al.
Publicado: (2018)

The Effect of SGLT2 Inhibition on Diabetic Kidney Disease in a Model of Diabetic Retinopathy
por: Matthews, Jennifer Rose, et al.
Publicado: (2022)

Current Knowledge of IL-6 Cytokine Family Members in Acute and Chronic Kidney Disease
por: Magno, Aaron L., et al.
Publicado: (2019)

SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Beiging
por: Matthews, Jennifer R., et al.
Publicado: (2020)

SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes
por: Herat, Lakshini Yasaswi, et al.
Publicado: (2023)

A cautionary note for researchers treating mice with the neurotransmitter norepinephrine
por: Matthews, Vance B., et al.
Publicado: (2018)

Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice
por: Herat, Lakshini Y, et al.
Publicado: (2020)

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—A Condition Associated with Heightened Sympathetic Activation
por: Carnagarin, Revathy, et al.
Publicado: (2021)

The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α
por: Magno, Aaron L., et al.
Publicado: (2020)

SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020)

TNFSF14-Derived Molecules as a Novel Treatment for Obesity and Type 2 Diabetes
por: Agostino, Mark, et al.
Publicado: (2021)

Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer
por: Hoyne, Gerard, et al.
Publicado: (2016)

Combined renal and common hepatic artery denervation as a novel approach to reduce cardiometabolic risk: technical approach, feasibility and safety in a pre-clinical model
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2021)

The ADAM metalloproteinases
por: Edwards, Dylan R., et al.
Publicado: (2008)

The Schlager mouse as a model of altered retinal phenotype
por: Herat, Lakshini Y., et al.
Publicado: (2019)

ADAM23 is downregulated in side population and suppresses lung metastasis of lung carcinoma cells
por: Ota, Masahide, et al.
Publicado: (2016)

Role for the metalloproteinase ADAM28 in the control of airway inflammation, remodelling and responsiveness in asthma
por: Bendavid, Guillaume, et al.
Publicado: (2023)

Regulation of A disintegrin and metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: The emerging role of tetraspanins and rhomboids
por: Matthews, Alexandra L., et al.
Publicado: (2017)

Retinal capillary rarefaction is associated with arterial and kidney damage in hypertension
por: Frost, Shaun, et al.
Publicado: (2021)

Supine blood pressure—A clinically relevant determinant of vascular target organ damage in hypertensive patients
por: Nolde, Janis M., et al.
Publicado: (2020)

ADAM9 is over‐expressed in human ovarian clear cell carcinomas and suppresses cisplatin‐induced cell death
por: Ueno, Mari, et al.
Publicado: (2018)

Microvascular changes at different stages of chronic kidney disease
por: Kannenkeril, Dennis, et al.
Publicado: (2020)

Role of ADAM and ADAMTS metalloproteinases in airway diseases
por: Paulissen, Genevieve, et al.
Publicado: (2009)

Peptide-Based Inhibitors of ADAM and ADAMTS Metalloproteinases
por: Pluda, Stefano, et al.
Publicado: (2021)

The disintegrin-metalloproteinases ADAM10 and ADAM17 are upregulated in cutaneous squamous cell carcinomas
por: Oh, S.-T., et al.
Publicado: (2016)

Microenvironment-derived ADAM28 prevents cancer dissemination
por: Gérard, Catherine, et al.
Publicado: (2018)

Immunomodulatory role of metalloproteinase ADAM17 in tumor development
por: Wang, Kai, et al.
Publicado: (2022)

Metalloproteinases ADAM10 and ADAM17 Mediate Migration and Differentiation in Glioblastoma Sphere-Forming Cells
por: Siney, Elodie J., et al.
Publicado: (2016)

ADAMTS and ADAM metalloproteinases in osteoarthritis – looking beyond the ‘usual suspects’
por: Yang, C.-Y., et al.
Publicado: (2017)

Molecular switch in human diseases-disintegrin and metalloproteinases, ADAM17
por: Yang, Guang, et al.
Publicado: (2021)

ADAM Metalloproteinase Domain 17 Regulates Cholestasis-Associated Liver Injury and Sickness Behavior Development in Mice
por: Almishri, Wagdi, et al.
Publicado: (2022)

Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice
por: Chalaris, Athena, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_e92u5krtl8ljfbtam8j1dpg7r4